Threshold (THLD) Data on TH-302 in Glioblastoma and Relapsed/Refractory Multiple Myeloma to Be Presented at ASCO 2014
Tweet Send to a Friend
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new clinical data from two ongoing Phase 1/2 clinical trials of its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE